Tag: pandemc

Gov. Tim Walz and Lt. Gov. Peggy Flanagan Update: July 9, 2021

Walz-Flanagan Update Banner

Governor Walz and Lt. Governor Flanagan Visited Rochester to Highlight Child Care and Early Education Investments in Minnesota’s COVID-19 Recovery Budget

Gov. and Lt. Gov. Highlight Child Care and Early Education Investments


On Thursday, Governor Tim Walz and Lt. Governor Peggy Flanagan visited Rochester to celebrate the passage of Minnesota’s COVID-19 Recovery Budget. The budget’s historic investments will help Minnesota’s working families by increasing access to affordable, high-quality child care, early education, and youth programs.

New Data Shows Minnesota’s COVID Restrictions Saved Lives

In case you missed it, KARE 11 aired a story this week detailing new research from the Wilder Foundation showing that Governor Walz’s leadership throughout the COVID-19 pandemic saved lives. Throughout the pandemic, CDC data shows Minnesota had the lowest death rate of any surrounding state. Rewatch the story here: New data shows Minnesota’s COVID restrictions saved lives.

Continue reading “Gov. Tim Walz and Lt. Gov. Peggy Flanagan Update: July 9, 2021”

Novavax vaccine protects against coronavirus in variant hot spots but proved less effective against strain in South Africa

Washington Post logo

A coronavirus vaccine made by Maryland biotech company Novavax proved effective at stopping symptomatic infections in global hot spots where concerning variants are dominant, the company announced Thursday. But warning signs lurked amid those findings: The protective effect of the vaccine was substantially muted in South Africa, where a worrisome virus variant is in wide circulation.

The data, presented by a company news release, is ominous news for other vaccine developers. They have been scrambling to determine whether current vaccines would remain effective against the variant found in South Africa and are designing new versions in case the virus can break through the protection provided by the shot. The data is the first, highly anticipated evidence of how well a vaccine performs against variants that have drawn global concern.

The company also noted that a third of the participants in its South African trial appeared to have already been infected with the original strain of coronavirus, based on antibodies in their blood when they were vaccinated. Some of those people became infected again, according to the company, suggesting natural immunity generated by an infection might not fully protect against the new variant. Continue reading.